These findings are consistent with previous studies on the effects of disease-specific PRS on the first breast cancers in BRCA1 and BRCA2 heterozygotes20,24 and with the higher relative prevalence of ER-negative and ER-positive contralateral breast cancers respectively, in this cohort. The gene discussed is BRCA1; the disease is breast cancer.